Acesis Biomed
About this raise
Acesis Biomed, with a valuation of $37.5 million, is raising funds on NetCapital. The company aims to develop a non-steroidal treatment to restore low testosterone in men. Acesis Biomed has developed a drug pipeline of short peptides targeting testosterone biosynthesis, which can induce the testis cells to produce the natural hormone. The company has two patents for its treatment, has received significant funding, and has strong animal preclinical data to support preclinical and future clinical programs. Dr. Konstantinos N. Karatzas and Dr. Vassilios Papadopoulos founded Acesis Biomed in October 2022. The current crowdfunding campaign has a minimum target of $10,001.60 and a maximum target of $1 million. The campaign proceeds will be used for collaborations, research and development, IP, and corporate expenses.
Investment Overview
Committed : $72,756
Deal Terms
Total Commitments
- Platform
- Netcapital
- Start Date
- 03/18/2025
- Close Date
- 04/30/2025
$10,002
$1,000,000
$251
Equity - Common
Early Stage
RegCF
$2.35
$37,490,629
Company & Team
Company
- Year Founded
- 2022
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B2C
- Margin
- Medium
- Capital Intensity
- High
Financials
-
Revenue
-
$0
as of FY2023
- Monthly Burn
-
$97,125
as of FY2023
-
Runway
-
0.2 months
as of Dec '23
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
Company Funding & Growth
Funding history
- Total Prior Capital Raised
- $2,737,485
- Grants
- $12,000,000
- VC Backed?
- No
| Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|
| 04/30/2025 | Netcapital | $37,490,629 | $72,756 | Equity - Common | Active | RegCF |